| Literature DB >> 35832528 |
Jing-Yu Xu1,2, An-Lan Zhao1,2, Ping Xin3, Jun-Ze Geng1,2, Bao-Juan Wang1,2, Tian Xia1,2.
Abstract
A higher incidence of female infertility has been reported with an unexpectedly early appearance in recent years. The female infertility treatment and application of assisted reproductive technology have recently gained immense interest from scientists. Many studies have discussed the beneficial effects of acupuncture on female infertility. With advancements in science and medical technology, acupuncture-related research has increased in investigating its effectiveness in treating female infertility. This review focuses on a compilation of research in recent years on acupuncture for female infertility treatment and the exploration of the underlying mechanism. For this purpose, literature was searched using various search engines like PubMed, Web of Science, and Google Scholar. The search was refined by only focusing on recent studies on acupuncture effectiveness and mechanism in female infertility and evaluating pregnancy outcomes.Entities:
Year: 2022 PMID: 35832528 PMCID: PMC9273356 DOI: 10.1155/2022/3854117
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
Characteristics of clinical studies.
| First author | Year | Research type | Type of infertility | Intervention | Course of treatment | Evaluating indicator | ||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||
| Andersen D | 2010 | RCT | IVF-ET | Acupuncture | N | 1 time | —— | CPR, PPR, LBR (−) |
| Moy I | 2010 | RCT | IVF-ET | Acupuncture | N | 1 time | —— | CPR (−) |
| Rashidi BH | 2013 | RCT | IVF-ET | Acupuncture | N | 4 times | NHQE⬆ | NRO, CPR, PPR, BPR (−) |
| Villahermosa DI | 2013 | RCT | IVF-ET | Acupuncture | N | 4 times | CPR⬆ | —— |
| Chen Q | 2015 | RCT | IVF-ET | Acupuncture | N | 12 weeks | (E2, P)⬆, EAI⬇ | CPR (−) |
| Jiang D | 2015 | RCT | PCOS | Acupuncture + WM | WM | 12 weeks | (CPR, ET/EM, CM)⬆, AR⬇ | —— |
| Wang X | 2016 | RCT | IVF-ET | Acupuncture | N | 30 times | (CPR, EM, Menstruation)⬆ | —— |
| Zhou L | 2016 | RCT | IVF-ET | Acupuncture | N | 15 ± 2 times | (E2, NRO, NHQE, CPR)⬆ | —— |
| Qu F | 2017 | RCT | IVF-ET | TEAS | N | 2 times | (CPR, LBR, NPY)⬆ | NRO, FR, NHQE, TGF- |
| Wu XK | 2017 | RCT | PCOS | Acupuncture + WM | WM | 16 weeks | —— | LBR (−) |
| Xu J | 2018 | RCT | PCOS | Acupuncture + WM | WM | 8 weeks | (CPR, COR)⬆, (T, LH)⬇ | AR, ET (−) |
| Yu L | 2018 | RCT | PCOS | Acupuncture + WM | WM | 24 times | (COR, ET/EM, E2, P)⬆ | CPR (−) |
| Altutunji AZ | 2019 | RCT | IVF-ET | Acupuncture | N | 2 weeks | (CPR, PPR, E2, P)⬆, OHSS incidence⬇ | AMH (−) |
| Kusuma AC | 2019 | RCT | IVF-ET | EA | False EA | 6 times | (NRO, FR, BCL-2)⬆, BAX⬇ | GDF9, BMP15 (−) |
| Shuai Z | 2019 | RCT | IVF-ET | TEAS | N | 16 ± 2 times | (CPR, LBR)⬆ | —— |
| Wu HC | 2019 | RCT | IVF-ET | EA | False EA | 12 weeks | (NHQE, CPR, PI3K/Akt mRNA)⬆ | NRO (−) |
| Dehghani AS | 2020 | RCT | IVF-ET | Acupuncture | N | 2 times | (CPR, PPR)⬆, BPR⬇ | —— |
| Guven PG | 2020 | RCT | IVF-ET | Acupuncture | N | 3 times | (CPR, PPR, LBR)⬆, STAI-1 score⬇ | —— |
| Xiang S | 2021 | RCT | IVF-ET | EA | N | 24 times | (NHQE, LBR, IRS-1/PI3K/GLUT4 mRNA)⬆ | NRO, CPR (−) |
| Zhai ZJ | 2021 | RCT | IVF-ET | TEAS (20 mA/30 mA/40 mA) | TEAS (5 mA) | 10–13 times | (NRO, ET)⬆ | NHQE, CPR (−) |
Note. T: Test group; C: Control group; RCT: Randomized controlled trial; IVF-ET: In vitro fertilization - embryo transfer; PCOS: Polycystic ovary syndrome; EA: Electroacupuncture; TEAS: Transcutaneous electrical acupoint stimulation; N: None; WM: Western medicine; CPR: Clinical pregnancy rate; PPR: Persistent pregnancy rate; LBR: live birth rate; BPR: Biochemical pregnancy rate; COR: Cycle ovulation rate; AR: Abortion rate; FR: Fertilization rate; NRO: Number of retrieved oocytes; NHQE: Number of high-quality embryos; ET: Endometrial thickness; EM: Endometrial morphology; EAI: Endometrial arterial impedance; CM: Cervical mucus; E2: Estradiol; P: Progesterone; STAI-1: State-trait anxiety inventory-1; OHSS: Ovarian hyperstimulation syndrome; NPY: Neuropeptide Y; TGF-α: Transforming growth factor-α; G-CSF: Granulocyte colony stimulating factor; BCL-2: B-cell lymphoma-2; BAX: Bcl2-Associated X; PI3K: Phosphatidylinositol-3-kinase; AKT: Protein kinase B; IRS-1: Insulin receptor substrate-1; GLUT4: Glucose transporter 4; GDF9: Growth differentiation factor 9; BMP15: Bone morphogenetic protein 15; ⬆: Improve; ⬇: Reduce; (−): Unchanged.
Characteristics of animal studies.
| First author | Year | Experimental object | Modeling drugs | Intervention | Course of treatment (times) | Evaluating indicator | |
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| Stener-victorin E | 2000 | PCO rats | EV | EA | 12 | NGF⬇ | Ovarian morphology (-) |
| Stener-victorin E | 2001 | PCO rats | EV | EA | 12 | CRF⬇ | —— |
| Stener-victorin E | 2003 | PCO rats | EV | EA | 12 | NGF⬇, ET-1⬇ | —— |
| Stener-victorin E | 2004 | PCO rats | EV | EA | 12 |
| NK cell, CD4 + /CD8 + T cell (-) |
| Zhang WY | 2009 | PCO rats | DHEA | Acupuncture | 5 | (NEI, Ovarian morphology, ET, E2)⬆, T⬇ | TSH, LH, P (-) |
| Huang J | 2020 | PCO rats | LE | EA | 14 | (AMH, PI3K, AKT)⬆, (T, LH, LC3 II/I)⬇ | Ovarian morphology (-) |
| Gao W | 2013 | ETF rats | Mifepristone | Acupuncture | 10 | (NEI, CCL2, CXCL8, uNK cell subsets)⬆ | —— |
| Zhu S | 2016 | COH mice | Gn | EA | 7 | (NEI, IGF-1)⬆ | —— |
| Wang S | 2019 | POF rats | CTX | Acupuncture | 21 | (E2, PI3K, Akt, BCL-2)⬆, (BAX, FSH)⬇ | Ovarian morphology (-) |
| Zhong H | 2019 | POF rats | CTX | EA | 7 | (NF, LS, E2, AMH)⬆, (PI3K, AKT, mTOR, S6K, 4E-BP1, FSH, LH)⬇ | —— |
Note. PCO: Polycystic ovary; ETF: Embryo transfer failure; COH: Controlled ovarian hyperstimulation; POF: Premature ovarian failure; EV: Estradiol valerate; DHEA: Dehydroepiandrosterone; LE: Letrozole; Gn: Gonadotropin; CTX: Cyclophosphamide; EA: Electroacupuncture; NGF: Nerve growth factor; CRF: Corticotropin releasing factor; ET-1: Endothelin-1; FSH: Follicle stimulating hormone; E2: Estradiol; T: Testosterone; ET: Endometrial thickness; NEI: Number of embryo implantation; LH: Luteinizing hormone; AMH: Anti-Mullerian hormone; LC3: Microtubule associated protein 1 light chain 3; PI3K: Phosphatidylinositol-3-kinase; AKT: Protein kinase B; CCL2: CC chemokine subfamily L2; CXCL8: CXC chemokine subfamily L8; IGF-1: Insulin growth factor; BCL-2: B-cell lymphoma-2; BAX: Bcl2-Associated X; NK cell: Natural killer cell; mTOR: mammalian target of rapamycin; S6K: S6 kinase; 4E-BP1: 4E-Binding Protein1; NF: Number of follicles; LS: Litter size; ⬆: Improve; ⬇: Reduce; (-): Unchanged.
Figure 1Mechanism of acupuncture in the treatment of infertility. The main function of acupuncture is to regulate reproductive related neuroendocrine signal molecules, in order to balance female reproductive endocrine, improve ovarian function, and promote embryo implantation. The symbol “⬆” represents increased expression and activity of the molecule, and the symbol “⬇” represents a decrease in the expression of this molecule. The symbol “+” represents positive feedback regulation, and the symbol “−” represents negative feedback regulation. Abbreviations are listed at the end of the article.
Figure 2Classification of the mechanisms of acupuncture in treating infertility. The symbol “⬆” represents increased expression and activity of the molecule, and the symbol “⬇” represents a decrease in the expression of this molecule.
Classification of clinical evaluation indexes of acupuncture in the treatment of infertility.
| Evaluation category | Specific items | |||
|---|---|---|---|---|
|
| ||||
|
| ||||
| Cervix | CM | ⬆ | —— | |
| Endometrium | EAI, ET, EM | ⬆ | —— | |
| Ovary | NRO, COR | ⬆ | —— | |
| Embryo | FR, NHQE | ⬆ | —— | |
| Menstruation | Menstrual regularity | ⬆ | —— | |
| Ovarian function markers | NPY, AMH, BCL-2, IRS-1, (PI3K, Akt, GLUT4) mRNA | ⬆ | BAX | ⬇ |
| Hormone level | E2, P | ⬆ | T, LH | ⬇ |
| Security | —— | OHSS incidence | ⬇ | |
|
| ||||
|
| ||||
| Pregnancy outcome | CPR, PPR, LBR | ⬆ | BPR, AR | ⬇ |
Note. CM: Cervical mucus; EAI: Endometrial arterial impedance; ET: Endometrial thickness; EM: Endometrial morphology; NRO: Number of retrieved oocytes; COR: Cycle ovulation rate; FR: Fertilization rate; NHQE: Number of high-quality embryos; NPY: Neuropeptide Y; AMH: Anti-Mullerian hormone; BCL-2: B-cell lymphoma-2; IRS-1: Insulin receptor substrate-1; PI3K: Phosphatidylinositol-3-kinase; AKT: Protein kinase B; GLUT4: Glucose transporter 4; BAX: Bcl2-Associated X; E2: Estradiol; P: Progesterone; T: Testosterone; LH: Luteinizing hormone; OHSS: Ovarian hyperstimulation syndrome; CPR: Clinical pregnancy rate; PPR: Persistent pregnancy rate; LBR: live birth rate; BPR: Biochemical pregnancy rate; AR: Abortion rate; ⬆: Improve; ⬇: Reduce.